TRT and Cardiovascular Health: What the TRAVERSE Trial Actually Shows (2026 Guide)

Executive Summary

Cardiovascular risk has been the most contested topic in TRT for over a decade. A 2010 trial was halted early over cardiovascular concerns. A 2014 observational study claimed TRT doubled heart attack risk. The FDA required a black-box warning. For years, men with heart disease were told TRT was off the table entirely — and cardiologists wrote blanket contraindications into institutional policy.

Then came TRAVERSE. The Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE trial — published in the New England Journal of Medicine in 2023 — was specifically designed to answer the cardiovascular safety question. With 5,246 men, a mean follow-up of 33 months, and a primary endpoint of major adverse cardiovascular events (MACE — heart attack, stroke, or cardiovascular death), TRAVERSE is the definitive dataset. Its conclusion: TRT was non-inferior to placebo for MACE in men with hypogonadism and pre-existing cardiovascular disease or elevated risk factors.

That non-inferiority finding removed the foundational justification for the categorical cardiovascular contraindication. However, TRAVERSE also identified a real signal: atrial fibrillation was significantly more common in the TRT arm. Pulmonary embolism showed a numerical increase that warrants attention in men with clot risk. Understanding what TRAVERSE actually showed — not the headline oversimplification — is what men and their providers need to make informed decisions. For the complete TRT safety overview, see TRT side effects. For the full protocol framework, see how to build a TRT protocol.

At-a-Glance Comparison

How the clinical understanding of testosterone and cardiovascular health has evolved. Based on TRAVERSE 2023 (NEJM), T-Trials, AHA/AUA 2024 guidance, and systematic reviews. Updated March 2026.

TRAVERSE: what the trial design, population, and primary endpoint actually showed

Men searching trt cardiovascular safety deserve the actual clinical result — not the pre-2023 conflicting data that still dominates Google search results. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The TRAVERSE trial was designed from the ground up to answer the cardiovascular safety question. Previous concerns came from observational studies with significant confounding, a single trial halted early based on a small number of events in a very different patient population, and mechanistic concerns about erythrocytosis and polycythemia. TRAVERSE was purpose-built to address these definitively.

TRAVERSE design:
— 5,246 hypogonadal men (total testosterone <300 ng/dL, two measurements)
— Aged 45–80 with established or high risk of cardiovascular disease
— Randomized to testosterone gel (targeting 350–750 ng/dL) vs placebo
— Median follow-up: 33 months (range up to ~5 years)
— Primary endpoint: time to first MACE (heart attack, stroke, or cardiovascular death) — specifically designed as a non-inferiority trial
— Published in New England Journal of Medicine, June 2023

Primary MACE result:
— MACE event rate: 7.0% in TRT arm vs 7.3% in placebo arm
— Hazard ratio: 1.02 (95% CI 0.82–1.27)
— Conclusion: Non-inferiority demonstrated — TRT did not significantly increase the risk of major cardiovascular events versus placebo in a high-cardiovascular-risk population

What non-inferiority means: This trial was not designed to show TRT is cardioprotective — it was designed to show it doesn't cause meaningful additional cardiovascular harm compared to placebo. That bar was met. The upper bound of the 95% confidence interval (1.27) means the trial can rule out a 27%+ increase in MACE — which, given the pre-TRAVERSE concern levels, was the clinically meaningful threshold.

Why this matters: The TRAVERSE population — men with hypogonadism and elevated cardiovascular risk or established CVD — is the population at highest cardiovascular concern with TRT. The non-inferiority finding in this population is the most relevant evidence for the real-world clinical decision. If TRT does not significantly increase MACE in men with prior cardiovascular events, the categorical contraindication for CVD history is not supported by current evidence. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: cardiologists and primary care physicians are still citing pre-2023 observational data to categorically deny TRT to men with cardiovascular history — when the largest RCT specifically designed for this population showed non-inferiority for the primary cardiovascular endpoint. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The atrial fibrillation signal: what TRAVERSE found and why it matters

The AFib finding from TRAVERSE is the cardiovascular signal that warrants the most attention for TRT in 2026 — and is underreported relative to the MACE result. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

While TRAVERSE established non-inferiority for MACE, it identified a pre-specified secondary endpoint that warrants ongoing clinical attention: atrial fibrillation was significantly more common in the TRT group.

TRAVERSE AFib findings:
— AFib incidence: 3.5% in TRT arm vs 2.4% in placebo arm
— Hazard ratio: 1.16 (95% CI 1.00–1.34, p=0.05)
— Absolute risk increase: approximately 1.1 percentage points over 33 months
— This was a pre-specified secondary endpoint (not a post-hoc finding), making it methodologically robust

FDA label update: Following TRAVERSE, the FDA updated the testosterone prescribing information to include AFib as a known risk. This is now part of the standard informed consent for TRT initiation.

Mechanistic hypotheses for the AFib signal:
— Testosterone has direct electrophysiological effects on cardiac ion channels, potentially increasing atrial ectopy in susceptible individuals
— Erythrocytosis-driven increases in blood viscosity may increase left atrial wall stress
— Water retention in the first weeks of TRT may temporarily increase cardiac preload
— The signal may be partly explained by baseline cardiac remodeling in hypogonadal men that creates substrate for AFib when androgenic stimulation is restored

Clinical implications:
— Men with a history of AFib, frequent palpitations, pre-existing atrial enlargement, or significant structural heart disease should have cardiology co-management before starting TRT
— Echocardiography and/or Holter monitoring may be appropriate for men with cardiac history before initiating TRT
— All men starting TRT should be counseled about AFib symptoms: irregular or rapid heartbeat, palpitations, exercise intolerance, or lightheadedness
— New palpitations after starting TRT warrant prompt evaluation, not watchful waiting

The AFib signal should not be conflated with the MACE result. AFib increases stroke risk if untreated, but with appropriate anticoagulation AFib is manageable — and the absolute risk increase in TRAVERSE was modest (~1.1%). The AFib signal is a reason for appropriate cardiology screening, not a categorical prohibition on TRT. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men with subclinical AFib or undiagnosed paroxysmal AFib start TRT without cardiac workup, develop symptomatic AFib, and go without anticoagulation — increasing stroke risk. Conversely, providers are using the AFib signal to deny TRT to all men with any cardiac history when the actual finding was a modest absolute risk increase requiring screening and monitoring, not prohibition. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

VTE, polycythemia, and blood clot risk: what the evidence shows and how to manage it

Men concerned about testosterone blood clots need to understand both the evidence for clot risk and the management approach that keeps hematocrit-driven risk controlled. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The clot risk with TRT is real but manageable, and directly linked to the erythrocytosis (elevated red blood cell mass) that testosterone-driven hematocrit elevation produces.

Mechanism: Testosterone stimulates erythropoiesis via EPO (erythropoietin), increasing red blood cell production and hematocrit. This increases blood viscosity, which can contribute to venous thromboembolism (DVT and pulmonary embolism) — particularly in men with underlying thrombophilia, immobility, or prior VTE.

TRAVERSE VTE findings:
— Pulmonary embolism: 0.9% (TRT arm) vs 0.5% (placebo arm) — numerically higher but did not reach statistical significance as an isolated endpoint
— Combined VTE (DVT + PE): similar between arms
— The non-significant PE signal is consistent with earlier observational data showing an association between TRT and PE in men with hypercoagulable states

FDA and clinical guidance on VTE:
— The FDA product label for testosterone includes venous thromboembolism as a known risk
— Men with prior VTE, known thrombophilia (Factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome), active malignancy with hypercoagulable state, or prolonged immobility are at elevated VTE risk on TRT

Managing erythrocytosis to control VTE risk:
— Baseline complete blood count (CBC) required before starting TRT
— Hematocrit at 3–6 months, then annually
— Target: hematocrit <54% (AUA/Endocrine Society consensus threshold)
— If hematocrit persistently exceeds 54%: dose reduction is first-line; if ineffective, therapeutic phlebotomy; if still uncontrolled, TRT discontinuation
— Hematocrit risk is injection-frequency dependent: weekly injections produce more stable levels than every-2-week injections, which produce higher peaks and more erythrocytosis. SubQ injection also shows lower HCT elevation vs IM in some studies.
— For complete polycythemia management, see TRT and blood donation

Contraindications for men with hypercoagulable states: A man with known Factor V Leiden and prior DVT requires hematologist co-management before TRT initiation — this is a high-risk combination that may make TRT inadvisable. Most hypogonadal men without prior VTE or known thrombophilia fall into the general population risk tier, where hematocrit monitoring provides adequate management. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men with undiagnosed thrombophilia or prior PE start TRT without appropriate clotting workup, develop a PE at elevated hematocrit, and attribute it to bad luck rather than an identifiable preventable risk factor. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

TRT and existing heart disease: the shift from prohibition to individualized risk assessment

The most clinically important change post-TRAVERSE is how providers should approach men with trt and existing cardiovascular disease — a population that TRAVERSE studied directly. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Pre-TRAVERSE, men with established coronary artery disease, prior myocardial infarction, or prior stroke were typically denied TRT based on theoretical risk and weak observational evidence. TRAVERSE changed this framework substantially.

Why TRAVERSE is specifically relevant to this population:
The TRAVERSE eligibility criteria required participants to have either:
— Documented cardiovascular disease (prior MI, coronary revascularization, stroke, TIA, or peripheral arterial disease), OR
— Multiple cardiovascular risk factors without established disease

This was not a study of healthy low-risk men. The non-inferiority finding for MACE applies directly to men with existing cardiovascular disease — which is the exact population historically denied TRT on cardiovascular grounds.

Current clinical positioning for men with CVD:
— Stable, established CVD (remote MI, prior revascularization, stable angina): TRT no longer categorically contraindicated; cardiology co-management recommended; careful monitoring of hematocrit and AFib risk
— Recent acute cardiovascular events: TRT should be deferred — typically 3–6 months post-MI or post-stroke until clinical stability is established. This is timing judgment, not a permanent contraindication.
— Severe uncontrolled heart failure (NYHA Class III–IV): TRT is not appropriate until hemodynamic stability is achieved; hypogonadism in severe HF is common and associated with poor prognosis, but TRT initiation requires cardiologist guidance
— Men on dual antiplatelet therapy or anticoagulants: TRT adds polycythemia and AFib risk on top of existing anticoagulation — requires close co-management

The positive evidence for hypogonadism management in CVD:
Hypogonadism is independently associated with increased cardiovascular mortality in multiple large cohort studies. Several mechanisms link low testosterone to cardiovascular risk: endothelial dysfunction, adverse lipid changes (low HDL, high triglycerides), increased visceral adiposity, insulin resistance, and reduced lean mass. Whether treating hypogonadism reduces cardiovascular mortality is not definitively established — TRAVERSE was powered for safety (non-inferiority), not efficacy on CV outcomes. But the direction of epidemiological evidence suggests low testosterone is a cardiovascular risk marker, not a protective state. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: cardiologists categorically deny TRT to their hypogonadal patients based on outdated guidance without reviewing TRAVERSE — perpetuating unnecessary suffering from hypogonadal symptoms in a population where current evidence supports TRT with appropriate monitoring. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The pre-TRAVERSE studies that created the cardiovascular concern — and why they were wrong

Understanding the history of testosterone cardiovascular risk research helps explain why categorical prohibitions were written into clinical guidelines — and why those guidelines needed updating. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The cardiovascular concern around TRT did not emerge from nowhere. Several high-profile studies created the narrative — and it is worth understanding what they actually showed and why the evidence quality was limited.

The key pre-TRAVERSE studies and their problems:

1. Basaria et al. (2010) — NEJM trial halted early:
A trial of TRT in older men with mobility limitations was stopped early because of a higher rate of cardiovascular events in the testosterone arm (5.5% vs 1% placebo over 6 months). This study enrolled very elderly men (mean age 74) with significant comorbidities — a population substantially different from the standard TRT candidate. It was also small (106 men) and underpowered. The trial's early termination inflates the apparent event rate. This single study generated disproportionate regulatory concern.

2. Finkle et al. (2014) — "TRT doubles heart attack risk":
This retrospective pharmacoepidemiological study claimed TRT doubled heart attack risk in the 90 days post-initiation. It used healthcare claims data without testosterone level measurements — meaning many men in the "TRT" arm were receiving treatment for obesity, fatigue, or other indications without confirmed hypogonadism. Healthy-user bias may also have been inverted: sicker men starting TRT for energy complaints were compared against healthier comparison groups. The study was widely criticized methodologically but generated enormous media attention.

3. Vigen et al. (2013) — "TRT increases CV events":
This observational study of VA patients contained a major data error: a correction was later issued because the abstract reported higher events in the TRT arm, but closer examination revealed that 10% of the "no testosterone" group had received testosterone and been miscoded. The direction of findings was called into question after the correction.

Contrast with higher-quality evidence:
Meta-analyses consistently show that when study quality is weighted (randomized controlled trials vs. observational data), TRT does not significantly increase cardiovascular events. The T-Trials — seven coordinated placebo-controlled trials in older hypogonadal men — found no significant increase in cardiovascular events. TRAVERSE, which was powered and designed specifically for CVD safety, provided the definitive RCT answer.

Regulatory context:
The FDA's 2015 label requirement for TRT products to include cardiovascular risk language — and the advisory to reserve TRT for men with confirmed hypogonadism, not age-related low T — was largely a response to the Finkle and Basaria studies. TRAVERSE data now provides the basis for a more nuanced regulatory and clinical position. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: men and providers are still operating on the 2014–2015 regulatory and media narrative without updating to the 2023 TRAVERSE findings — denying treatment based on evidence that has since been substantially revised. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Cardiovascular monitoring on TRT: the practical checklist for safe management

The post-TRAVERSE framework for trt and heart health monitoring is more about proactive surveillance than prohibition — and the right questions to ask your provider. Buyers searching for trt and heart health usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

A responsible TRT provider will implement the following cardiovascular-relevant monitoring protocol, integrating AUA, Endocrine Society, and post-TRAVERSE guidance.

Before starting TRT:
1. Complete blood count (CBC) — baseline hematocrit for erythrocytosis monitoring
2. Blood pressure measurement — document baseline; optimize hypertension before starting
3. Cardiac history review — document any prior AFib, MI, stroke, heart failure, arrhythmias, or valvular disease
4. Thrombophilia history — prior DVT/PE, known clotting disorders, family history of VTE
5. Lipid panel — TRT has modest effects on lipids (may slightly reduce HDL in some men; variable LDL effects); document baseline
6. Cardiology referral if: recent (within 6 months) acute cardiovascular event; known AFib; significant heart failure (NYHA II+); known thrombophilia with prior VTE

At 3–6 months after initiating TRT:
1. Repeat CBC — hematocrit surveillance; address >54% with dose reduction
2. Blood pressure check
3. Symptom review: palpitations, irregular heartbeat, exertional chest pain, dyspnea, leg swelling

Annually thereafter:
1. Annual CBC, BP, lipid panel, symptom review
2. Urology referral for: hematocrit persistently >54% despite dose reduction; new palpitations or irregular rhythm; unexplained exertional symptoms

Questions to ask your TRT provider:
— What is your hematocrit monitoring protocol and threshold for intervention?
— Do you assess for AFib history before prescribing?
— What do you recommend if I develop palpitations after starting?
— How do you adjust the protocol if my hematocrit rises above target?

Providers who cannot answer these questions clearly are not running appropriate cardiovascular safety surveillance. For a provider comparison including monitoring quality, see best online TRT clinics compared. For hematocrit management specifically, see TRT and blood donation. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: telehealth TRT platforms that compete on speed compress or eliminate cardiovascular baseline workup — prescribing to men with recent MI or undiagnosed AFib without appropriate screening, or failing to monitor hematocrit and missing polycythemia before it drives a PE. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

The cardiovascular evidence has been fundamentally revised — but the right TRT provider needs to implement proactive monitoring, not just prescribe and disappear. Use our provider comparison tool to find clinics that include baseline CBC, defined hematocrit thresholds, AFib screening, and cardiology referral pathways.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does TRT cause heart attacks?

The best available evidence — the TRAVERSE trial (NEJM 2023, 5,246 men, 33-month median follow-up) — showed TRT was non-inferior to placebo for major adverse cardiovascular events (MACE: heart attack, stroke, or cardiovascular death). The hazard ratio was 1.02 with a 95% confidence interval of 0.82–1.27, ruling out a meaningful increase in MACE. Earlier observational studies that claimed elevated heart attack risk had significant methodological limitations and have not been replicated in higher-quality RCT evidence.

What did the TRAVERSE trial show about TRT and cardiovascular safety?

TRAVERSE (NEJM 2023) was a 5,246-man randomized controlled trial of hypogonadal men with elevated cardiovascular risk. Its primary finding: TRT was non-inferior to placebo for major cardiovascular events (MACE). Secondary findings included a significantly higher rate of atrial fibrillation in the TRT arm (3.5% vs 2.4%, p=0.05) and a numerically higher but non-significant pulmonary embolism rate. TRAVERSE is the largest and most rigorous cardiovascular safety study ever conducted on TRT and represents the current standard of evidence.

Can I use TRT if I've had a heart attack?

The TRAVERSE trial enrolled men with established cardiovascular disease — including prior MI — and found TRT non-inferior to placebo for further cardiovascular events. The categorical prohibition on TRT after MI is not supported by current evidence. However, timing matters: most guidelines recommend deferring TRT for 3–6 months after an acute MI while hemodynamic stability is established. Cardiology co-management is recommended for men with significant cardiovascular history starting TRT.

Does TRT cause atrial fibrillation?

Yes — TRAVERSE found a statistically significant increase in AFib: 3.5% in the TRT arm vs 2.4% in placebo (HR 1.16, p=0.05). The FDA updated the testosterone product label to include AFib risk following TRAVERSE. The absolute risk increase was approximately 1.1 percentage points over 33 months — a real signal that warrants informed consent, AFib history screening before starting TRT, and prompt evaluation of new palpitations or irregular heartbeat on TRT.

Does TRT increase blood clot risk?

TRT increases hematocrit (red blood cell concentration) through testosterone-driven erythropoiesis. Elevated hematocrit increases blood viscosity and venous thromboembolism (VTE) risk — particularly in men with thrombophilia or prior DVT/PE. TRAVERSE showed a numerically higher pulmonary embolism rate in the TRT arm (0.9% vs 0.5%) that did not reach statistical significance. Standard management is hematocrit monitoring with a target of <54%, dose reduction if exceeded, and therapeutic phlebotomy for persistent elevation.

Can I use TRT if I have atrial fibrillation?

Possibly — but AFib history warrants cardiology co-management before and during TRT. The TRAVERSE AFib signal means men with pre-existing AFib have a baseline arrhythmia substrate that TRT may exacerbate. Whether TRT is appropriate depends on AFib type, current anticoagulation status, underlying structural heart disease, and how well-controlled the AFib is. This is a shared decision with a cardiologist, not a telehealth TRT platform decision.

Does TRT raise or lower cholesterol?

TRT has modest and variable effects on lipids. In most studies, TRT slightly reduces HDL (good cholesterol) — typical range 2–5 mg/dL reduction. Effects on LDL and total cholesterol are inconsistent. TRAVERSE did not show meaningful cardiovascular harm despite these lipid effects, suggesting the modest HDL reduction is not clinically significant in the context of physiologic TRT. Baseline lipid panel documentation and monitoring is standard practice.

What is polycythemia from TRT and why is it a cardiovascular concern?

Polycythemia (erythrocytosis) is an elevated red blood cell mass. TRT stimulates EPO-driven red blood cell production, raising hematocrit. When hematocrit exceeds approximately 54%, blood viscosity increases substantially — raising venous thromboembolism risk and potentially increasing cardiac workload. The AUA/Endocrine Society consensus threshold for intervention is hematocrit >54%, addressed by dose reduction, injection frequency adjustment, or therapeutic phlebotomy. For complete management guidance, see the TRT and blood donation article.

Should I see a cardiologist before starting TRT?

For most hypogonadal men without significant cardiac history, cardiology referral is not required before TRT — baseline CBC, blood pressure, and clinical history review are sufficient. Cardiology co-management is recommended for: prior AFib or significant arrhythmia history; recent acute cardiovascular event (within 3–6 months); significant heart failure (NYHA Class II+); multiple uncontrolled cardiovascular risk factors; prior VTE with known thrombophilia. The decision is risk-stratified, not reflexive.

What does hypogonadism do to cardiovascular health?

Untreated hypogonadism is independently associated with adverse cardiovascular markers: endothelial dysfunction, unfavorable lipid profiles (low HDL, elevated triglycerides), increased visceral adiposity, insulin resistance, metabolic syndrome, and reduced lean mass. Multiple large cohort studies associate low testosterone with increased cardiovascular mortality. Whether TRT reverses these risks and reduces cardiovascular events is not definitively established — TRAVERSE was designed to show safety (non-inferiority), not efficacy on CV outcomes. But the decision framework is now risk-versus-risk, not treatment-risk-versus-no-risk.

Can TRT cause a stroke?

Stroke was part of the primary MACE endpoint in TRAVERSE. The trial showed no significant increase in MACE — including stroke — in the TRT arm compared to placebo. Individual stroke risk could theoretically be elevated via AFib-related embolism (TRAVERSE AFib signal) or polycythemia-driven thrombosis, but neither effect was large enough to produce a statistically significant MACE difference. Men with prior stroke should discuss TRT timing and cardiology co-management, with most guidelines recommending a minimum 3–6 month deferral after acute cerebrovascular events.